ClinicalTrials.gg
RecruitingNCT07366593Updated Jan 26, 2026

Immune Profile and Respiratory Parameters in Down Syndrome Children With Acute Pneumonia: Pre-Intervention Analysis

An observational study in Down Syndrome, sponsored by Badr University. Recruiting at 2 sites in Egypt. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Badr University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
40
Ages
1 Year to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Down Syndrome with a site in Egypt — 5 open to participants now, 7 under way, none of them phase 3. Down Syndrome · Egypt.

Started
2025
with 5 others
Observational
6 of 21
2 open now
Registered
18th of 21
by date
Lead sponsor
1 of 21
Badr University

Among the 21 studies in Down Syndrome with a site in Egypt, this one is one of 6 that started in 2025, is one of 6 observational ones, and was the 18th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

5 of the 21 studies in Down Syndrome with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 1 Year to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Down Syndrome with a site in Egypt, or all of them as a file.
02

Study summary

Baseline serum IgG, IgA, IgM (nephelometry), total WBC count (automated analyzer), RR (manual count), and SaO2 (pulse oximetry) were measured. Pearson or Spearman correlations were used to assess relationships between immune and respiratory variables, and with age

Read the detailed description

descriptive, cross-sectional study analyzed baseline data from 40 children with DS and acute pneumonia enrolled prior to intervention in a larger trial. Baseline serum IgG, IgA, IgM (nephelometry), total WBC count (automated analyzer), RR (manual count), and SaO2 (pulse oximetry) were measured. Pearson or Spearman correlations were used to assess relationships between immune and respiratory variables, and with age.

03

Conditions studied

  • Down Syndrome

Keywords

  • Down Syndrome, pneumonia, immune, oxygen saturation
04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Data collection occurred at the inpatient pediatric ward of King Abdulaziz University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Down Syndrome with acute bronchopneumonia
  • sufficient cognitive ability

Exclusion criteria

Exclusion Criteria:

  • severe congenital heart defects
  • primary immunodeficiencies
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No

Interventions

  • ProcedurePearson or Spearman correlations were used to assess relationships between immune and respiratory variables, and with age

    Baseline serum IgG, IgA, IgM (nephelometry), total WBC count (automated analyzer), RR (manual count), and SaO2 (pulse oximetry) were measured. Pearson or Spearman correlations were used to assess relationships between immune and respiratory variables, and with age.

06

What researchers measure

Primary outcomes

  1. serum IgG, IgA, IgM

    Immunoglobulins: Concentrations of IgG(mg/dl) IgA,(mg/dl) and IgM (mg/dl) were determined from serum using an automated nephelometer

    Time frame: Upon enrollment and prior to any intervention baseline data were collected

  2. Respiratory Rate

    Respiratory rate (breaths/minute) was determined by direct observation and counting of chest wall movements over one full minute

    Time frame: Upon enrollment and prior to any intervention baseline data were collected

  3. Arterial Oxygen Saturation (SaO2)

    Peripheral oxygen saturation (%) was measured non-invasively via pulse oximetry

    Time frame: Upon enrollment and prior to any intervention baseline data were collected

  4. White Blood Cell count

    Total WBC count (thousands/mm³) was measured from a whole blood sample using an ADVIA 120 automated hematology analyzer

    Time frame: Upon enrollment and prior to any intervention baseline data were collected

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The investigators have not yet determined whether individual participant data will be shared. Any future decision will depend on institutional policies, ethical considerations, and applicable data protection regulations."

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jan 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 26, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Jan 30, 2026
CompletionEst.
Jan 30, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07366593
Lead sponsor
Badr University
Responsible party
Mona Mohamed Abdelkhalek (assistance professor, Badr University) — Principal investigator
First posted
Jan 26, 2026
Start date
Jul 1, 2025
Primary completion
Jan 30, 2026 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Mona Mohamed Abdelkhalek, assistance prof
Contact
3m.sons@gmail.com
002021024056108
Mona Mohamed Abdelkhalek, assistance prof
Contact
Mona.Abdelkhalek@buc.edu.eg
002021024056108

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion